leadf
logo-loader
viewVentriPoint Diagnostics Ltd.

Ventripoint Diagnostics increases placing to $1.5M due to demand

The proceeds will be used for sales and marketing, development and general working capital

Pictured is Canadian currency
The company has closed the order book on the offering and intends to complete the offering of debenture units at $1,000 per unit by January 25 this year

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) has increased its previously announced non-brokered private placement to $1.5 million from $1 million due to investor demand.

The proceeds will be used for sales and marketing, development and general working capital, the Toronto-based, heart-focused medtech company said in a statement.

READ: Ventripoint Diagnostics arranges C$1M private placement of debenture units

The company has closed the order book on the offering and intends to complete the offering of debenture units at $1,000 per unit by January 25 this year.

Each unit of the offering will include a principal amount of C$1,000 in convertible, unsecured debentures maturing in three years, as well as 6,000 common share purchase warrants, with each warrant exercisable for one common share at C$0.175 per share for 18 months.

The debentures will have an annual interest rate of 6.5%, and the company may pay a finder's fee of up to 7% of the gross proceeds.

Ventripoint uses an artificial intelligence (AI) method known as knowledge-based reconstruction to create applications monitoring heart disease.

Contact Giles at giles@proactiveinvestors.com

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.08 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

on 15/10/20

2 min read